Search hospitals > Kansas > Independence
Cancer Center of Kansas-Independence
Claim this profileIndependence, Kansas 67301
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Relapse
Conducts research for Stomach Cancer
303 reported clinical trials
2 medical researchers
Summary
Cancer Center of Kansas-Independence is a medical facility located in Independence, Kansas. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Relapse, Stomach Cancer and other specialties. Cancer Center of Kansas-Independence is involved with conducting 303 clinical trials across 419 conditions. There are 2 research doctors associated with this hospital, such as Shaker Dakhil, M.D. and Dennis F. Moore.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
ER negative
Top PIs
Shaker Dakhil, M.D.Ascension Via Christi Hospitals Wichita6 years of reported clinical research
Expert in Skin Cancer
Expert in Lung Cancer
83 reported clinical trials
170 drugs studied
Dennis F. MooreAscension Via Christi Hospitals Wichita4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
30 reported clinical trials
80 drugs studied
Clinical Trials running at Cancer Center of Kansas-Independence
Breast Cancer
Lung Cancer
Breast cancer
Bladder Carcinoma
Bladder Cancer
Skin Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Multiple Myeloma
Squamous Cell Carcinoma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cancer Center of Kansas-Independence?
Cancer Center of Kansas-Independence is a medical facility located in Independence, Kansas. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Relapse, Stomach Cancer and other specialties. Cancer Center of Kansas-Independence is involved with conducting 303 clinical trials across 419 conditions. There are 2 research doctors associated with this hospital, such as Shaker Dakhil, M.D. and Dennis F. Moore.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.